Literature DB >> 17003064

What is the rationale for hydrocortisone treatment in children with infection-related adrenal insufficiency and septic shock?

Rajesh Aneja1, Joseph A Carcillo.   

Abstract

Recent studies show that children who die from fulminant meningococcaemia have very low cortisol:adrenocorticotrophic hormone (ACTH) ratios within the first 8 h of presentation to emergency facilities compared with survivors. This observation supports the possibility that adrenal insufficiency may contribute to rapid cardiovascular collapse in these children. In recent years, the use of hydrocortisone treatment has become increasingly popular in the care of adult and paediatric patients with septic shock. In this review, the classical adrenal insufficiency literature is presented and the existing rationale for using titrated hydrocortisone treatment (2-50 mg/kg/day) to reverse catecholamine-resistant shock in children who have absolute adrenal insufficiency (defined by peak cortisol level <18 microg/dl after ACTH challenge) or pituitary, hypothalamic or adrenal axis insufficiency is provided. In addition, the concept of relative adrenal insufficiency (basal cortisol >18 microg/dl but a peak response to ACTH <9 microg/dl) is reviewed. Although there is a good rationale supporting the use of 7 days of low-dose hydrocortisone treatment (about 5 mg/kg/day) in adults with this condition and catecholamine resistant septic shock, the paediatric literature suggests that it is prudent to conduct more studies before recommending this approach in children.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17003064      PMCID: PMC2083316          DOI: 10.1136/adc.2005.088450

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  48 in total

1.  Physiological approach to successful treatment of endotoxin shock in the experimental animal.

Authors:  R C LILLEHEI; L D MACLEAN
Journal:  AMA Arch Surg       Date:  1959-03

2.  Clinical application of a new test of pituitary reserve.

Authors:  G W LIDDLE; H L ESTEP; J W KENDALL; W C WILLIAMS; A W TOWNES
Journal:  J Clin Endocrinol Metab       Date:  1959-08       Impact factor: 5.958

3.  ICU physicians should abandon the use of etomidate!

Authors:  Djillali Annane
Journal:  Intensive Care Med       Date:  2005-01-27       Impact factor: 17.440

4.  Absolute and relative adrenal insufficiency in children with septic shock.

Authors:  Cristiane F Pizarro; Eduardo J Troster; Durval Damiani; Joseph A Carcillo
Journal:  Crit Care Med       Date:  2005-04       Impact factor: 7.598

5.  Adrenal failure in the critically ill.

Authors:  M Duggan; I Browne; C Flynn
Journal:  Br J Anaesth       Date:  1998-09       Impact factor: 9.166

6.  Admission cortisol and adrenocorticotrophic hormone levels in children with meningococcal disease: evidence of adrenal insufficiency?

Authors:  F A Riordan; A P Thomson; J M Ratcliffe; J A Sills; M J Diver; C A Hart
Journal:  Crit Care Med       Date:  1999-10       Impact factor: 7.598

7.  Endocrine and metabolic responses in children with meningoccocal sepsis: striking differences between survivors and nonsurvivors.

Authors:  K F Joosten; E D de Kleijn; M Westerterp; M de Hoog; F C Eijck; E V Voort; J A Hazelzet; A C Hokken-Koelega
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

8.  A retrospective cohort study of prognostic factors associated with outcome in pediatric severe sepsis: what is the role of steroids?

Authors:  Barry P Markovitz; Denise M Goodman; R Scott Watson; David Bertoch; Jerry Zimmerman
Journal:  Pediatr Crit Care Med       Date:  2005-05       Impact factor: 3.624

9.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

10.  Adrenocortical function during septic shock.

Authors:  G Bouachour; P Tirot; J P Gouello; E Mathieu; J F Vincent; P Alquier
Journal:  Intensive Care Med       Date:  1995-01       Impact factor: 17.440

View more
  7 in total

1.  Effect of high dose of steroid on plateletcount in acute stage of dengue Fever with thrombocytopenia.

Authors:  K C Shashidhara; K A Sudharshan Murthy; H Basavana Gowdappa; Abhijith Bhograj
Journal:  J Clin Diagn Res       Date:  2013-07-01

2.  Steroids in septic shock: the confusion continues.

Authors:  Shane M Tibby
Journal:  Arch Dis Child       Date:  2007-07       Impact factor: 3.791

3.  Effects of low-dose hydrocortisone therapy on immune function in neonatal horses.

Authors:  Kelsey A Hart; Michelle H Barton; Michel L Vandenplas; David J Hurley
Journal:  Pediatr Res       Date:  2011-07       Impact factor: 3.756

Review 4.  Adrenocortical insufficiency in horses and foals.

Authors:  Kelsey A Hart; Michelle H Barton
Journal:  Vet Clin North Am Equine Pract       Date:  2011-04       Impact factor: 1.792

Review 5.  Advances in monitoring and management of shock.

Authors:  Haifa Mtaweh; Erin V Trakas; Erik Su; Joseph A Carcillo; Rajesh K Aneja
Journal:  Pediatr Clin North Am       Date:  2013-03-29       Impact factor: 3.278

6.  Using newborn screening analytes to identify cases of neonatal sepsis.

Authors:  Deshayne B Fell; Steven Hawken; Coralie A Wong; Lindsay A Wilson; Malia S Q Murphy; Pranesh Chakraborty; Thierry Lacaze-Masmonteil; Beth K Potter; Kumanan Wilson
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

7.  Collaborative pediatric critical care research network: looking back and moving forward.

Authors:  Douglas F Willson; J Michael Dean; Kathleen L Meert; Christopher J L Newth; Kanwaljeet J S Anand; John Berger; Rick Harrison; Jerry Zimmerman; Joseph Carcillo; Murray Pollack; Richard Holubkov; Tammara L Jenkins; Carol Nicholson
Journal:  Pediatr Crit Care Med       Date:  2010-01       Impact factor: 3.624

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.